Superworth

Strata Critical Medical SRTA

Medical - Care Facilities, Healthcare
$4.66
−1.06%
Market cap
$412.3M
PE
n/m
not a meaningful number
Forward PE
n/m
not a meaningful number
Price to sales
1.6×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$256M
+49% on a year ago
Net margin
15.7%
Free cash flow yield
−11.7%

Strata Critical Medical trades at 1.6× sales. Revenue was $256M over the last twelve months, up 49% on a year earlier with a 16% net margin.

Charts

Financials

Income statement for SRTA, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$71.4M+56%$47.5M+25%$51.5M+14%$67.9M+11%$36.1M−50%$54.4M+15%$35.9M−30%$45.1M−34%$49.3M+37%$66.8M+23%$67.4M+87%$72.5M+61%
Cost of revenue$55.9M+53%$38.5M+16%$41.4M+9%$51.6M+2%$28.6M−49%$41.8M+9%$28.9M−30%$36.1M−30%$37.7M+32%$55.1M+32%$53.3M+84%$57.3M+59%
Gross profit$15.6M+68%$9M+81%$10.1M+42%$16.4M+58%$7.5M−52%$12.6M+40%$7.1M−30%$9M−45%$11.6M+55%$11.7M−7%$14.1M+100%$15.2M+69%
R&D$1.1M−47%$988K−39%$670K−40%$971K−33%$417K−61%$743K−25%$812K+21%$915K−6%$453K+9%n/an/an/a
SG&A$22M+24%$43.7M+90%$19.3M+3%$27.5M+30%$14.2M−35%$20.2M−54%$12.3M−36%$13.3M−52%$16.8M+18%$16.8M−17%$15.6M+27%$14M+5%
−$7.4M−29%−$35.6M+81%−$9.9M−23%−$12.1M−1%−$7.1M−5%−$8.4M−77%−$5.7M−42%−$4.6M−62%−$5.6M−21%−$6.4M−24%−$3M−48%−$5.4M+17%
Pre-tax income$418K−$35M+115%−$4.3M−58%−$11.3M−11%−$5.6M−$9.9M−72%−$1.6M−63%−$3.4M−70%−$9.7M+72%−$5.4M−46%$2.4M−$10.5M+209%
$129K+130%−$1M+24%−$84K−57%$52K$0$0$0$0$0$0$0$0
Net income$289K−$33.9M+120%−$4.2M−59%−$11.3M−7%−$2M−$9.8M−71%−$3.5M−18%−$3.7M−67%$57.4M−$8.8M−10%$2.2M−$10.5M+181%
$0.00−$0.45+105%−$0.06−57%−$0.15−12%−$0.03−$0.12−73%−$0.04−33%−$0.05−67%$0.70−$0.10−17%$0.03−$0.12+140%
81M+13%74.8M+4%75.8M+5%77.6M+6%78M−4%78.5M+5%79.9M+5%81.3M+5%82.5M+6%84.7M+8%90.2M+13%86.2M+6%

Gross profit: 18 periods, Q4 FY20 to Q3 FY25: not printed by the filing, worked out from its own lines.

EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Care Facilities nearest Strata Critical Medical's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
SRTAStrata Critical Medical$412.3Mn/m10.6×1.6×+49%15.7%
VMDViemed Healthcare$373.3M27.2×26.1×1.2×+25%4.8%
SBCSBC Medical$543M11.2×8.2×3.1×−7%28.0%
OMDAOmada Health$1.2B316×341×3.7×+48%1.4%
USPHU S Physical Therapy$1.3B101×42.1×1.6×+11%4.0%
PNTGPennant$1.5B46.5×47.0×1.3×+38%2.9%
ARDTArdent Health$1.7B22.3×8.5×0.3×+3%1.2%
HCSGHealthcare Services$1.7B14.7×26.1×0.9×+4%6.6%
PGNYProgyny$2.2B31.5×55.1×1.7×+6%6.0%
ADUSAddus HomeCare$2.3B21.4×32.4×1.5×+16%7.1%
MDPediatrix Medical$2.4B14.0×13.4×1.2×+1%9.0%
Peer median$1.6B24.8×29.2×1.4×+8%5.4%

Investors who own it

Investors we follow who held Strata Critical Medical at the end of Jun 30, 2026, from their 13F filings.

More on Strata Critical Medical

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Care Facilities
Sector
Healthcare

Valuation data, not investment advice. Prices as of .